AI CAPITAL INTELLIGENCE
希格生科 · Series A+ · CNY 200,000,000–900,000,000 (reported range) · 2026-11-04
Financing facts, at a glance
希格生科: financing disclosed on 2026-11-04, Series A+, CNY 200,000,000–900,000,000 (reported range). Named investors: 国寿股权投资有限公司. This is the amount disclosed for the financing, not a company valuation or an individual investor commitment.
希格生科 is recorded in the Industry AI / Drug discovery & life sciences segment. The disclosed financing is Series A+, with an amount of CNY 200,000,000–900,000,000 (reported range). Named investors include 国寿股权投资有限公司.
- Disclosed company name
- 希格生科（深圳）有限公司
- Disclosure date
- 2026-11-04
- Round
- Series A+
- Financing amount
- CNY 200,000,000–900,000,000 (reported range)
- Market coverage
- China
- Sector
- Industry AI / Drug discovery & life sciences
- Product form
Disclosed investors
国寿股权投资有限公司
Sources for this round
- 希格生科完成国寿股权领投的数亿元A+轮融资首关
news.pedaily.cn · Original publication date not recorded
Historical and background sources
- 希格生科完成8000万元 A轮融资
nbd.com.cn · Original publication date not recorded
Collection batch . Reported ranges and lower bounds are retained. Financing proceeds are not company valuation.
Citation and coverage
Compiled and linked by Wavesight AI. Financing facts are attributable to the original disclosure sources; coverage is our recorded sample, not the whole market.
Wavesight AI｜希格生科 · Series A+ · CNY 200,000,000–900,000,000 (reported range) · 2026-11-04。希格生科: financing disclosed on 2026-11-04, Series A+, CNY 200,000,000–900,000,000 (reported range). Named investors: 国寿股权投资有限公司. This is the amount disclosed for the financing, not a company valuation or an individual investor commitment. Compiled and linked by Wavesight AI. Financing facts are attributable to the original disclosure sources; coverage is our recorded sample, not the whole market. https://www.zkdlj.vip/en/funding/FI-7138d99fd221db57/#conclusion-overview
Link to conclusion